Daniel R. Vlock, MD
Dr. Vlock brings extensive pharmaceutical industry and academic experience in pharmaceutical drug development. Dr. Vlock is founder and CEO of Alopexx Pharmaceuticals which developed and licensed a fully human monoclonal antibody directed against S. aureus. That antibody was recently licensed to Sanofi Aventis. He has also held senior-level medical and research positions at GPC Biotech, Inc., Pharmacia Corporation, Ethicon Endo-Surgery (a subsidiary of Johnson & Johnson Company), and Boehringer Ingelheim Pharmaceuticals, Inc., where he was involved in the development of numerous oncology drugs, medical devices and drug-device combinations. While at Pharmacia he ran the Celebrex Oncology Group. That group ran 2 large international cancer prevention trials (over 3500 patients) and was also responsible for the successful approval of Celebrex for the treatment of Familial Adenomatous Polyposis, a life-threatening pre-cancerous condition. This was the first drug ever approved for cancer prevention. While at other companies he ran programs which successfully developed and introduced 2 monoclonal antibodies into clinical trials. Prior to moving to industry, Dr. Vlock was on the faculty at Harvard Medical School, University of Pittsburgh School of Medicine and Yale University School of Medicine where he led laboratory and clinical programs in tumor immunology.
Dr. Vlock received his A.B. from Cornell University and an M.D. from Baylor College of Medicine. He completed a research fellowship in clinical immunology at Baylor College of Medicine, an internship and medical residency at Temple University Hospital and a senior medical residency and fellowship in medical oncology at Yale New Haven Hospital.